MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...

The applicants say the plant would generate enough electricity to supply about 78,018 local households annually. | ITV News ...

FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026MINNEAPOLIS, (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: ...

Ranchi: The Jharkhand Academic Council (JAC) extended the last date for submission of application forms for the Akanksha-40 entrance examination to Ja.

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif. Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the ...

The FDA has accepted a New Drug Application (NDA) for Celcuity’s gedatolisib in hormone receptor positive (HR+), human ...

HONG KONG, Jan. 19, 2026 /PRNewswire/ -- (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatmen ...

Aegis Critical Energy Defence Corp. (CSE: QESS) (OTCQB: QESSF) (FSE: JG6) ("Aegis") is pleased to congratulate Quantum eMotion Corp. (TSXV: QNC) (OTCQB: QNCCF) (FSE: 34Q0) on filing its Form 40-F ...

Buganda Road Chief Magistrate’s Court has further remanded Kampala lawyer Sarah Bireete, director of the Centre for ...

QRX003 could become the first ever approved treatment for Netherton SyndromeASHBURN, Va., (GLOBE NEWSWIRE) -- Quoin ...

If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026QRX003 could become the first ever approved treatment for Netherton Synd ...